Well, technically the week after... and then after a little delay. But still. If the FDA ok's toric for the US the launch will all fit in q2. That means, hopefully, a marketing blitz and rep hires! Should be a little pent-up demand to cover it though.
ServiceMax gets 70 million... which IS a lot pre-IPO. Beats what TOA got anyway. Allows them to market the legs of Astea any time they want... In perspective, Astea Zack's hold on the company only allowed them to get 2 million for cloud developments. Well, IF the 2m went to the cloud.. though it might just got to fund the wait. Prior to that they got a few more million in 2008. None of this is really at-risk either: the 2008 money gets a 10% guaranteed dividend (Zack guarantees). Time will soon tell if it is worth the wait. It is not quite true that Astea had the market to itself... but it had the most know-how-not! ... of few players. Now it's getting crowded. ServiceMax has 100+ m at-risk looking for a billion-dollar ipo. We are at 15-20 m or so AFTER the ipo.
For the first time in a while,market cap here is now clearly way above what it is over there.... was about on par last few months. Not that that is a heck of a lot, same stock price here as 8 years ago... cos there's more stock and less cash! Over there, they seemed to have lost it, for now. I there were a merger today, the boot would be on the other foot...
You can outsource the work, but not the risk. This should not have happened on deVivo's watch... shows again, like the salesforce fiasco, that little companies are more fragile than S&N. Luck for him he had a little painkiller to give us = bit of growth. Another one would be the ok on the pancreas ide.Since he had the chance to pre-warn, we can now assume an ok quarter. Might be worth something?
15% dilution might knock us back to 10ish. BUT that depends on who buys. An investor buyer will not flip the shares... and hopeful possibility that we will be back to 12 after the offering! .. since then the dilution event will be in the mirror.
The new rather confident-sounding CFO gave guidance of higher than 40-50% growth for non-US sales fro 2014. Their export sales are 30% single-shot... the market might not be! Since Mitek is the re-seller and heard of the FDA approval a day earlier there is no way Anika will give guidance on their behalf. Add to that Mitek does not seemingly inform Anika of their inventory position or strategy, so Anika cannot know. US market is said to be 45%ish single-shot... so one can assume that the ONLY non-animal source will have its share, whether efficacy is no better. One has to trust that Mitek is incentivized by the huge margin they make. What is a positive here is that Anika margin is likely the same on both export sales and US sales (no sales to Japan!) unlike most other companies which suffer margin compression on good export sales. A normal positive surprise would be an immediate stocking order for the single-shot product... but it needs to be made and shipped in 4 weeks for q1.
This stock price action looks very much like bdsi. A low-floater suddenly shoots up on enormous volume, drops 25% on highish volume and then gradually rises back to new highs. Point being you can't trust "the voting machine" until volume somehow normalizes. Or then maybe not.
What is maybe different now to 7yrs ago is that Mitek is unlikely to give up the 3-shot market believing it will become irrelevant... Not likely that growth will slow down due to monovisc, so we should see growth in ortho way over 20% for the YEAR.
Corrected that title there, ex-US sales were "only" growing 30% y-y! Also not that Mitek will launch Monovisc in 12 days time at the biggest show of the year. Convenient. Lot of misinformation here... So, on the call said that Monovisc will erode growth in sales of Orthovisc, not the sales. Note also that Mitek sales are what count, which is 20% growth, rest is inventory adjustment. What IS true is that Anika q reported sales EARLIER were a few million to inventory NOT to Mitek customers. Whether that earlier was q3, 2013 or just built up - not said. Sterile, non-animal HA has a long shelf-life I believe.
Mitek is driving this business, which is why sherwood will not guide (and wanted own salesforce). It's quite clear that if Mitek is #2 in a 900 m business and Anika gets only 50ish m in sales, then Mitek's margins are staggeringly high in absolute terms.
Former CEO was from Siemens, most corrupting co. in the world...Poland is one level above Ukraine, so, 2+2, issue is 100% corruption. Aubrey should have seen that, or maybe was part of it. Pity, since EU cash is swamping Poland with roads to nowhere... now isns are out.
Looking at volume, few are willing to sell much at these prices, so building a position or increasing one raises the price. Enough good news has been given, rest is mechanistic.Reverse would be true, too. For a cloud stock, liquidity is terrible!
Still looking for a tipping point on micropulse. They had a slide earlier where it was said to be a money-maker to use laser vs. drugs in the US... so outcome equivalence should seal it. If we get a drug that stops AMD in its tracks, then the laser would be the one-time treatment to clear up the existing symptoms.
For a co. going bk 5 or more irix is oddly over-capitalized! Need to work harder on that... little add-on acq. would be nice... and get that inventory down...
First time growth in US +35% outdid that at CSI... assuming there 28% growth was even. Now they have another indication coming and a massive increase in salesfeet. Pity no-one asked about CSI's 360 trial. These can always be nasty when a company-sponsored trial can be tweaked to get the answer the sponsor wants. Seems here the message is that not all calcium is a problem, hmm. Hopefully they have data to back that up big time.
ISR is the same product as plain vanilla variety: would be nice if they could engineer a differential.